eXoZymes
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
750 Royal Oaks Dr Ste 106, Monrovia, Cal...Website
www.exozymes.comRevenue
$6.6 MillionStock Symbol
EXOZIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About eXoZymes
Co-founders Tyler Korman, PhD, and Paul Opgenorth, PhD, detail how the concept of liberating enzymes from cellular confines was born in Jim Bowies UCLA lab. They share how this vision evolved into Invizyne in 2019, highlighting the pioneering research, bold experiments, and challenges overcome along the way.Explore more
eXoZymes Org Chart
PO
Development (Founder & Vice President)
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is eXoZymes your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if eXoZymes had a recent Job posting/layoffs
Funding: Get notified immidiatlly once eXoZymes has new funding data
Check if eXoZymes has recently received funding, and reach out quickly before it becomes old news!
eXoZymes, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when eXoZymes launches new products
Congratulate Masked Content for being promoted to Masked Content at eXoZymes
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if eXoZymes is spiking on competitors!
Earning: See what the market has to say on eXoZymes recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined eXoZymes as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
eXoZymes is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
eXoZymes is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about eXoZymes.
Most Recent Scoops
Person-Based
Contracts
Project
eXoZymes is developing the Acclaim, a fully implanted cochlear device featuring a piezoelectric sensor that captures mechanical vibrations from the incus bone, a modular chest-located battery pack providing three to five days between recharges and an estimated 10 to 12 year lifespan, and a skull-mounted processor with no external components or magnets.
Product Development
Project
eXoZymes has reported that its lead molecule NCT was developed in 11 months for under $1 million using its cell-free platform, compared to years and tens of millions of dollars required by conventional synthetic biology approaches, with a pipeline that also includes cannabinoids, a fragrance compound, and additional compounds in proof-of-concept development.
Proof of Concept (POC), Research & Development
Project
eXoZymes has completed enrollment of 56 patients across seven sites in its pivotal trial for the Acclaim fully implanted cochlear device, with all patients activated and through one-month visits, 12-month data collection expected to conclude at the end of Q1 next year, and an FDA submission planned for Q2 of next year targeting potential approval as early as the end of 2027 or the first half of 2028, supported by FDA Breakthrough Device designation.
Product Development, Medical Research, Clinical Operations
Project
Quality Assurance, Manufacturing Operations
eXoZymes News & Media
eXoZymes Q2 Earnings Call Highlights
eXoZymes (NASDAQ:EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select a manufacturing partner by the end of the third quarter and identify a market laueXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
Total non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company’s platform eXoZymes Inc. (NASDAQ:EXOZ) LOS ANGELES, CA, UNITED STATES, June 25, 2026 /EINPresswire.com/ -- eXoZymes Inc. (NASDAQ: …eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
eXoZymes Inc. (NASDAQ:EXOZ) LOS ANGELES, CA, UNITED STATES, June 10, 2026 /EINPresswire.com/ -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes” or “Company”) - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable …EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
EXoZymes Inc (EXOZ) showcases its innovative biomanufacturing platform and strategic focus on NCT and cannabinoids, while navigating financial hurdles and market skepticism.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding eXoZymes
Sign Up For FreeTo access detailed company insights
Co-founders Tyler Korman, PhD, and Paul Opgenorth, PhD, detail how the concept of liberating enzymes from cellular confines was born in Jim Bowies UCLA lab. They share how this vision evolved into Invizyne in 2019, highlighting the pioneering research, bold experiments, and challenges overcome along the way.... Read More
